SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM and an IC50 value of 0.7797 μM. It demonstrates antitumor effects on ovarian cancer both in vivo and in vitro, induces apoptosis, and shows remarkable antitumor efficacy in renal cell carcinoma (RCC). It also suppresses ovarian cancer growth by inhibiting proliferation, inducing apoptosis and cell death, and potentially inhibiting angiogenesis.
- Inhibits proliferation of ovarian cancer cells
- Induces apoptosis and cell death
- Upregulates expression of p53, p21, and PUMA
- Demonstrates antitumor activity in xenograft models
- Effectively suppresses tumor growth in nude mice